目的 分析遼寧省腫瘤醫(yī)院2020—2022年單抗類靶向藥物的使用情況以及變化趨勢(shì)，為臨床抗腫瘤藥安全合理經(jīng)濟(jì)用藥提供參考依據(jù)。方法 收集2020—2022年遼寧省腫瘤醫(yī)院?jiǎn)慰诡惏邢蛩幬锸褂脭?shù)據(jù)，分析銷售金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）以及排序比（B/A）。結(jié)果 2020—2022年單抗類靶向藥物銷售金額逐年增長(zhǎng)。貝伐珠單抗和曲妥珠單抗連續(xù)3年銷售金額排名前2位。帕妥珠單抗由2020年的第5位增長(zhǎng)到2022年的第3位。曲妥珠單抗DDDs連續(xù)3年均排在第1位。2022年新增品種（維迪西妥單抗、維布妥昔單抗、達(dá)雷妥尤單抗等）銷售金額和DDDs排名均相對(duì)靠后，但其DDC值較高。地舒單抗、曲妥珠單抗、帕妥珠單抗、伊尼妥單抗等的DDC值較低，且B/A＞1，利妥昔單抗、貝伐珠單抗的B/A＜1。結(jié)論 2020—2022年遼寧省腫瘤醫(yī)院?jiǎn)慰诡惏邢蛩幬锏慕Y(jié)構(gòu)總體上較為合理，能滿足患者的醫(yī)療需求，保障患者用藥的安全、有效和經(jīng)濟(jì)。

Objective To analyze the usage and variation tendency of monoclonal antibody targeting drugs in Liaoning Cancer Hospital & Institute from 2020 to 2022, and provide references for standardizing the management and rational application. Methods Consumption sum, DDDs, DDC, and drug sequence ratio of monoclonal antibody targeting drugs in Liaoning Cancer Hospital & Institute from 2020 to 2022 were analyzed statistically. Results From 2020 to 2022, the sales amount of monoclonal antibody targeting drugs increased year by year. Bevacizumab and trastuzumab ranked top 2 in consumption sum for 3 consecutive years. Pertuzumab increased from 5th place in 2020 to 3rd place in 2022. Trastuzumab DDDs ranked the first place for 3 consecutive years. The consumption sum and DDDs of the new varieties (disitamab vedotin, brentuximab vedotin, daratumumab, etc.) in 2022 were relatively lower, but their DDC value was higher. The DDC values of denosumab, trastuzumab, pertuzumab, and inetetamab were low, and the sequencing ratio was >1, while the sequencing ratio of rituximab and bevacizumab was < 1. Conclusion From 2020 to 2022, the use of monoclonal antibody targeting drugs in Liaoning Cancer Hospital & Institute is generally reasonable. It can meet the medical needs of patients and guarantee the safety, effectiveness and economy of medication for patients.

R979.1

遼寧省腫瘤醫(yī)院質(zhì)譜課題項(xiàng)目(ZP202019)